Skip to content
DataLookout
Menu

STARTERNCT06352307

Clinical Phenotypes, Natural History, and Long-Term Outcomes of Arrhythmogenic Cardiomyopathy: The STARTER Registry

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 20 years 4 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 31, 2050 Show 9 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 1500 → 4500 participants
    • Eligibility criteria expanded, about 269 words
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Secondary endpoints expanded, about 104 words
    • Study description expanded, about 400 words
    • Site details revised
    • Study title expanded, about 3 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2024 to Apr 9, 2024
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Time to First Composite Serious Ventricular Arrhythmic Event
Timeframe: Time to First Composite Serious Ventricular Arrhythmic Event

Secondary (17)

First Occurrence of Sustained Ventricular Tachycardia or Ventricular Fibrillation
Incidence of Sudden Cardiac Death
First Occurrence of Appropriate Implantable Cardioverter-Defibrillator Therapy
Occurrence of Heart Failure Hospitalization
All-Cause Mortality
Show 12 moreShow less
Cardiovascular Mortality
Occurrence of Heart Transplantation
Initiation of Long-Term Mechanical Circulatory Support
Rate of Recurrent Serious Ventricular Arrhythmic Events
Recurrence of Ventricular Arrhythmia After Catheter Ablation
Proportion of Patients With Changes in Ventricular Phenotype
Change in Left Ventricular Ejection Fraction
Change in Right Ventricular Ejection Fraction
Change in Left Ventricular End-Diastolic Volume Index
Change in Right Ventricular End-Diastolic Volume Index
Presence of Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging
Ventricular Distribution of Late Gadolinium Enhancement

Arms and interventions

Retrospective Cohort

Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) and available medical records from January 1, 2018, through October 1, 2026, will be included retrospectively. Existing clinical data, including medical history, ventricular phenotype, electrocardiographic findings, cardiac imaging, genetic testing results when available, treatments, and documented clinical outcomes, will be collected and analyzed. Patients will be classified according to right-dominant, left-dominant, or biventricular ACM phenotypes. No research-specific interventions, additional examinations, or new biospecimen collection will be performed as part of retrospective data collection.

Prospective Cohort

Patients of all ages with a clinical diagnosis of arrhythmogenic cardiomyopathy (ACM) will be prospectively enrolled and followed under routine clinical care. Clinical, electrocardiographic, imaging, genetic, treatment, and outcome data will be collected. Patients will be classified as having right-dominant, left-dominant, or biventricular ACM. Follow-up will generally occur at 6 months, 12 months, and annually during years 2 through 5 to assess serious ventricular arrhythmias, sudden cardiac death, heart failure-related events, and changes in cardiac phenotype. Optional biospecimens may be collected with appropriate consent and ethical approval. No experimental treatments or research-mandated invasive procedures will be performed.

Sites

1 site in 1 country

  • First Affiliated Hospital of Xi'an Jiantong UniversityXi'an, Shaanxi, China